Baxter International | BAX - Assets


Baxter International reported $19.85B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Abbott USD 110.43B 23.72B Mar/2026
AngioDynamics USD 269.68M 4.04M Sep/2025
Artivion USD 883.16M 1.64M Mar/2026
AtriCure USD 643.99M 10.19M Mar/2026
Avanos Medical USD 1.05B 23.6M Mar/2026
Baxter International USD 19.85B 209M Mar/2026
Becton, Dickinson and Co. USD 50.83B 4.01B Mar/2026
Boston Scientific USD 44.35B 678M Mar/2026
Cooper Companies USD 12.42B 29.4M Dec/2025
Dexcom USD 6.63B 293.4M Mar/2026
Edwards Lifesciences USD 13.32B 376M Mar/2026
Fresenius EUR 41.4B 1.07B Dec/2025
Globus Medical USD 5.44B 136.79M Mar/2026
Halozyme Therapeutics USD 2.67B 147.4M Mar/2026
ICU Medical USD 4.01B 36.74M Mar/2026
Inogen USD 307.01M 5.03M Sep/2025
Insulet USD 2.99B 203.2M Mar/2026
Integra LifeSciences USD 3.58B 24.28M Mar/2026
Intuitive Surgical USD 20.11B 347.7M Mar/2026
J&J USD 200.89B 1.68B Mar/2026
Laboratory Of America USD 19.09B 694.4M Mar/2026
Masimo USD 1.64B 56.2M Mar/2026
Medtronic USD 91.48B 139M Dec/2025
Merit Medical Systems USD 2.72B 33.36M Mar/2026
Quest Diagnostics USD 16.67B 448M Mar/2026
Smith & Nephew USD 10.69B 150M Dec/2025
Stryker USD 46.29B 1.55B Mar/2026
Tandem Diabetes Care USD 1.15B 272.28M Mar/2026
Teleflex USD 6.78B 164.24M Mar/2026
Terumo JPY 2.31T 55.3B Mar/2026
Zimmer Biomet Holdings USD 22.72B 370.1M Mar/2026